Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02951156
Registration number
NCT02951156
Ethics application status
Date submitted
19/10/2016
Date registered
1/11/2016
Date last updated
17/12/2020
Titles & IDs
Public title
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Query!
Scientific title
PHASE 1B/PHASE 3 MULTICENTER STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION REGIMENS THAT INCLUDE AN IMMUNE AGONIST, EPIGENETIC MODULATOR, CD20 ANTAGONIST AND/OR CONVENTIONAL CHEMOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) JAVELIN DLBCL
Query!
Secondary ID [1]
0
0
2016-002904-15
Query!
Secondary ID [2]
0
0
B9991011
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Javelin DLBCL
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Diffuse Large B-Cell Lymphoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Avelumab
Other interventions - Utomilumab
Other interventions - Rituximab
Other interventions - Azacitidine
Treatment: Drugs - Bendamustine
Treatment: Drugs - Gemcitabine
Treatment: Drugs - Oxaliplatin
Experimental: Phase 1b Arm A - avelumab/utomilumab/rituximab
Experimental: Phase 1b Arm B - avelumab/utomilumab/azacitidine
Experimental: Phase 1b Arm C - avelumab/rituximab/bendamustine
Experimental: Phase 3 Arm D (selected from Phase 1b) - Selected regimen from Phase 1b component which may be i) avelumab/utomilumab/rituximab OR ii) avelumab/rituximab/azacitidine OR iii) avelumab/rituximab/bendamustine
Active Comparator: Phase 3 Arm E - Investigator's Choice of either rituximab/bendamustine or rituximab/gemcitabine/oxaliplatin
Other interventions: Avelumab
Investigational fully human anti-PD-L1 monoclonal antibody
Other interventions: Utomilumab
Investigational, fully human IgG2 CD 137/4-1BB agonist
Other interventions: Rituximab
CD20-directed cytolytic antibody
Other interventions: Azacitidine
Antimetabolite antineoplastic agent and demethylation agent.
Treatment: Drugs: Bendamustine
Alkylating drug
Treatment: Drugs: Gemcitabine
Nucleoside analogue
Treatment: Drugs: Oxaliplatin
Platinum-based drug
Query!
Intervention code [1]
0
0
Other interventions
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Dose Limiting Toxicities (DLT)
Query!
Assessment method [1]
0
0
AEs occurring in first 4 weeks of treatment,attributable to 1 of study drugs. Hematology:1)Grade 4 neutropenia,2)Grade >=3 febrile neutropenia with single temperature of >38.3 degrees Celsius (C)/sustained temperature of >=38.0 degrees C for more than 1 hour with/without associated sepsis,3)Grade >=3 neutropenic infection,4)Grade 4 thrombocytopenia/Grade 3 thrombocytopenia with clinically significant bleeding,5)Grade 4 anemia 6)Any grade >=3 non-hematology toxicity except:transient Grade 3 flu like symptoms/fever controlled with standard medical management;transient Grade 3 fatigue,localized skin reactions/headache that resolves to Grade <=1;Grade 3 nausea,vomiting/diarrhea resolved to Grade <=1 in ?72 hours after initiation of adequate medical management;Grade 3 skin toxicity resolved to Grade <=1 in ?7 days;tumor flare;Single laboratory values that are out of normal range,that have no clinical correlate and resolve to Grade <=1 within 7 days with adequate medical management.
Query!
Timepoint [1]
0
0
Day 1 Cycle 1 up to 4 Weeks
Query!
Primary outcome [2]
0
0
Objective Response Rate (ORR) as Assessed by Investigator Per Lugano Response Classification Criteria
Query!
Assessment method [2]
0
0
ORR was defined as percentage of participants with complete response (CR) or partial response (PR), as assessed by investigator per lugano response classification criteria. CR was defined as a score of 1 (no uptake above background), 2 (uptake less than or equal to [<=] mediastinum), or 3 (uptake less than [<] mediastinum but <=liver) with or without a residual mass on PET 5-point scale (5-PS), for lymph nodes and extralymphatic sites; no new lesions; no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. PR was defined as >=50% decrease in SPD of up to six of the largest dominant lymph nodes, no increase in size of other nodes, liver, or spleen volume, a >=50% decrease in sum of products of diameters (SPD) of hepatic and splenic nodules, absence of other organ involvement, and no new sites of disease.
Query!
Timepoint [2]
0
0
Randomization until date of PD, start of new anticancer therapy, discontinuation from study or death due to any cause, whichever occurred first (maximum up to 36 months)
Query!
Secondary outcome [1]
0
0
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Greater Than or Equal to (>=) Grade 3, As Per National Cancer Institute Common Terminology Criteria For Adverse Events (NCI-CTCAE), Version 4.03
Query!
Assessment method [1]
0
0
AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per NCI-CTCAE version 4.03,severity was graded as Grade 1:asymptomatic/mild symptoms,clinical/diagnostic observations only, intervention not indicated; Grade 2:moderate, minimal, local/noninvasive intervention indicated,limiting age-appropriate instrumental activities of daily life (ADL); Grade 3:severe/medically significant but not immediately life-threatening, hospitalization/prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4:life-threatening consequence, urgent intervention indicated; Grade 5:death related to AE. TEAE was defined as events which occurred during on-treatment period beginning with first dose of study treatment through minimum (30 days + last dose of study treatment or start of new anti-cancer drug therapy). In this outcome measure participant with any TEAE of Grade 3 or above are reported.
Query!
Timepoint [1]
0
0
From first dose of study treatment up to at least 30 days after the last dose of study treatment or initiation of new anti-cancer therapy (up to 36 months)
Query!
Secondary outcome [2]
0
0
Number of Participants With Laboratory Abnormalities As Per National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE), Version 4.03
Query!
Assessment method [2]
0
0
Laboratory parameters included hematological and biochemistry: Hematological parameters included: anemia, haemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased and white blood cells decreased. Biochemistry parameters included alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, cholesterol high, creatine kinase(cpk) increased, creatinine increased, gamma glutamyl transferase(ggt) increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypertriglyceridemia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, lipase increased,serum amylase increased.Test abnormalities were graded by NCI CTCAE version 4.03 as Grade 1=mild; Grade 2=moderate; Grade 3/Grade 4=severe/life-threatening. Number of participants with abnormalities of any grade were reported.
Query!
Timepoint [2]
0
0
From first dose of study treatment up to at least 30 days after the last dose of study treatment or initiation of new anti-cancer therapy (up to 36 months)
Query!
Secondary outcome [3]
0
0
Number of Participants With Electrocardiogram (ECG) Abnormalities
Query!
Assessment method [3]
0
0
ECG abnormalities included: 1) QT interval, QT interval corrected using Bazett's formula (QTcB) and QT interval corrected using Fridericia's formula (QTcF): increase from baseline greater than (>) 30 millisecond (ms) or 60 ms; absolute value >450 ms, >480 ms and >500 ms; 2) heart rate (HR): absolute value <=50 beats per minute (bpm) and decrease from baseline >=20 bpm; absolute value >=120 bpm and increase from baseline >=20 bpm; 3) PR interval: absolute value >=220 ms and increase from baseline >=20 ms; 4) QRS interval: absolute value >=120 ms.
Query!
Timepoint [3]
0
0
From first dose of study treatment up to at least 30 days after the last dose of study treatment or initiation of new anti-cancer therapy (up to 36 months)
Query!
Secondary outcome [4]
0
0
Duration of Response (DOR) as Assessed by Investigator Per Lugano Response Classification Criteria
Query!
Assessment method [4]
0
0
Investigator assessed DOR: was defined for participants with OR as time from first documentation of OR to time of first documentation of disease progression/death due to any cause, whichever occurred first. CR: score of 1(no uptake above background),2(uptake <=mediastinum),or 3(uptake <mediastinum but <=liver) with or without a residual mass on PET 5-PS,for lymph nodes extralymphatic sites;no new lesions;no evidence of FDG-avid disease in bone marrow. PR: >=50% decrease in SPD of up to 6 of largest dominant lymph nodes,no increase in size of other nodes,liver,spleen volume,>=50% decrease in SPD of hepatic splenic nodules,absence of other organ involvement,no new sites of disease. PD: appearance of new lesion more than 1.5 cm in any axis,at least a 50% increase from nadir in SPD/longest diameter of previous lesion/node. Data was censored on date of last adequate tumor assessment in participants with no event,started new anti-cancer therapy/had 2 or more missing assessments.
Query!
Timepoint [4]
0
0
First response (CR or PR) to date of PD, start of new anti-cancer therapy, discontinuation from the study, censoring date or death due to any cause, whichever occurred first (maximum up to 36 months)
Query!
Secondary outcome [5]
0
0
Time to Tumor Response (TTR) as Assessed by Investigator Per Lugano Response Classification Criteria
Query!
Assessment method [5]
0
0
TTR was defined for participants who achieved objective response as time from randomization to first documentation of objective tumor response (CR or PR) that was subsequently confirmed. CR was defined as a score of 1 (no uptake above background), 2 (uptake <= mediastinum), or 3 (uptake <mediastinum but <=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow. PR was defined as >=50% decrease in SPD of up to six of the largest dominant lymph nodes, no increase in size of other nodes, liver, or spleen volume, a >=50% decrease in SPD of hepatic and splenic nodules, absence of other organ involvement, and no new sites of disease.
Query!
Timepoint [5]
0
0
From the date of randomization to the first documentation of objective response (CR or PR) (maximum up to 36 months)
Query!
Secondary outcome [6]
0
0
Disease Control Rate as Assessed by the Investigator Per Lugano Response Classification Criteria
Query!
Assessment method [6]
0
0
Disease control rate was defined as percentage of participants with disease control. Disease Control (DC) was defined as the best overall response of CR, PR, or stable disease (SD). CR: score of 1 (no uptake above background), 2 (uptake <= mediastinum), or 3 (uptake less than <mediastinum but <=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow. PR: >=50% decrease in SPD of up to six of the largest dominant lymph nodes, no increase in size of other nodes, liver, or spleen volume, a >=50% decrease in SPD of hepatic and splenic nodules, absence of other organ involvement, and no new sites of disease. SD: <50% decrease in SDP of up to 6 dominant, measurable nodes and extranodal sites; no criteria for progressive disease met. To qualify as a best overall response of SD, at least one SD assessment must be observed >=6 weeks after start date and before disease progression.
Query!
Timepoint [6]
0
0
From the date of randomization to the first documentation of PD, study discontinuation, start of new anti-cancer therapy or death due to any cause, whichever occurred first (maximum up to 36 months)
Query!
Secondary outcome [7]
0
0
Progression-Free Survival (PFS) as Assessed by the Investigator Per Lugano Response Classification Criteria
Query!
Assessment method [7]
0
0
Investigator assessed PFS was defined as time (in months) from date of randomization to the first documentation of disease progression or death (due to any cause), whichever occurred first. PFS data was censored on the date of the last adequate tumor assessment for participants who had no an event (PD or death), for participants who start a new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing or inadequate post-baseline tumor assessment. Participants without an adequate baseline or post-baseline tumor assessment were censored on the date of randomization unless death occurred on or before the time of the second planned tumor assessment in which case the death was considered as an event.
Query!
Timepoint [7]
0
0
From the date of randomization to progression of disease, study discontinuation, censoring date or death due to any cause, whichever occurred first (up to 36 months)
Query!
Secondary outcome [8]
0
0
Overall Survival
Query!
Assessment method [8]
0
0
Overall survival was defined as the time (in months) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.
Query!
Timepoint [8]
0
0
From the date of randomization to discontinuation from the study or death, whichever occurred first (maximum up to 36 months)
Query!
Secondary outcome [9]
0
0
Concentration Verses Time Summary of Avelumab
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
1 hour Post dose Day 2 Cycle 1, 144 hour Post dose Day 8 of Cycle 1, 0 hour Post dose Day 16 of Cycle 1, Day 1 of Cycle 4 and Cycle 6
Query!
Secondary outcome [10]
0
0
Number of Participants With Anti-Drug Antibodies (ADA) Against Avelumab by Never and Ever Positive Status
Query!
Assessment method [10]
0
0
ADA never-positive was defined as no positive ADA results at any time point. ADA ever-positive was defined as at least one positive ADA result at any time point.
Query!
Timepoint [10]
0
0
Baseline: 2 hours pre-dose of first dose of avelumab, Post baseline: post first dose up to up to 30 Days after the end of treatment (maximum up to 36 months)
Query!
Secondary outcome [11]
0
0
Number of Participants With Anti-Drug Antibodies (ADA) Against Rituximab by Never and Ever Positive Status
Query!
Assessment method [11]
0
0
ADA never-positive was defined as no positive ADA results at any time point. ADA ever-positive was defined as at least one positive ADA result at any time point.
Query!
Timepoint [11]
0
0
From the date of first study treatment up to 30 Days after the end of treatment (maximum up to 36 months)
Query!
Secondary outcome [12]
0
0
Number of Participants With Anti-Drug Antibodies (ADA) Against Utomilumab by Never and Ever Positive Status
Query!
Assessment method [12]
0
0
ADA never-positive was defined as no positive ADA results at any time point. ADA ever-positive was defined as at least one positive ADA result at any time point.
Query!
Timepoint [12]
0
0
From the date of first study treatment up to 30 Days after the end of treatment (maximum up to 36 months)
Query!
Secondary outcome [13]
0
0
Number of Participants With Neutralizing Antibodies (nAb) Against Avelumab by Never and Ever Positive Status
Query!
Assessment method [13]
0
0
nAb never-positive was defined as no positive nAb results at any time point and nAb ever-positive was defined as at least one positive nAb result at any time point.
Query!
Timepoint [13]
0
0
From the date of first study treatment up to 30 Days after the end of treatment (maximum up to 36 months)
Query!
Secondary outcome [14]
0
0
Number of Participants With Neutralizing Antibodies (nAb) Against Rituximab by Never and Ever Positive Status
Query!
Assessment method [14]
0
0
nAb never-positive was defined as no positive nAb results at any time point and nAb ever-positive was defined as at least one positive nAb result at any time point.
Query!
Timepoint [14]
0
0
From the date of first study treatment up to 30 Days after the end of treatment (maximum up to 36 months)
Query!
Secondary outcome [15]
0
0
Number of Participants With Neutralizing Antibodies (nAb) Against Utomilumab by Never and Ever Positive Status
Query!
Assessment method [15]
0
0
nAb never-positive was defined as no positive nAb results at any time point and nAb ever-positive was defined as at least one positive nAb result at any time point.
Query!
Timepoint [15]
0
0
From the date of first study treatment up to 30 Days after the end of treatment (maximum up to 36 months)
Query!
Secondary outcome [16]
0
0
Programmed Death Receptor-1 Ligand-1 (PD-L1) Biomarker Expression in Tumor and Immune Cells as Assessed by Immunohistochemistry (IHC) at Baseline
Query!
Assessment method [16]
0
0
Percentage of Tumor and Immune Cells as Assessed by Immunohistochemistry at Baseline.
Query!
Timepoint [16]
0
0
Screening (prior to first dose of study treatment)
Query!
Secondary outcome [17]
0
0
Number of Participants With Minimal Residual Disease Burden (MRD) Positive, Negative and Not Evaluable (NE) Status
Query!
Assessment method [17]
0
0
Number of participants with MRD positive, negative and not evaluable status were reported in this outcome measure.
Query!
Timepoint [17]
0
0
Baseline, Day 1 of Cycle 3, 6, 9, 12 and 18
Query!
Eligibility
Key inclusion criteria
Key
-Any of the following as defined by the WHO, 2016 lymphoid neoplasm classifications and
histologically confirmed:
- Diffuse large B-cell lymphoma (DLBCL), Not Otherwise Specified (NOS): Germinal center
B-cell type (GCB), Activated B-cell type (ABC)
- High-grade B-cell lymphoma (HGBCL) NOS
- HGBCL with MYC and BCL2 and/or BCL6 rearrangements
- T-cell histocyte-rich large B-cell lymphoma
- EBV+ DLBCL, NOS
- HHV8+ DLBCL, NOS
Relapsed or refractory disease following at least 2 lines (and a maximum of 4 lines) of
prior rituximab containing multi-agent chemotherapy which may include an autologous stem
cell transplantation unless patients are not considered suitable for intensive second-line
chemotherapy or autologous stem cell transplantation. Patients who are ineligible for
intensive second line chemotherapy,must have received at least one prior
rituximab-containing combination chemotherapy regimen. Patients who are ineligible for
intensive second line chemotherapy, must have received at least one prior
rituximab-containing combination chemotherapy regimen.
- Baseline measurable disease with at least 1 bi dimensional lesion with longest
diameter (LDi) >1.5cm on CT scan which is FDG avid on PET scan.
- A biopsy (archived or Screening/recent) will be collected at Screening.
- At least 18years of age (or =20 years in Japan).
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Active central nervous system (CNS) lymphoma.
- Prior organ transplantation including prior allogeneic SCT.
- Prior therapy with an anti PD 1, anti PD L1, anti PD L2, anti CD137, or anti cytotoxic
T lymphocyte associated antigen 4 (CTLA 4) antibody (including ipilimumab,
tremelimumab or any other antibody, or drug specifically targeting T cell co
stimulatory or immune checkpoint pathways).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
16/12/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
2/12/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
29
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
St. George Hospital - Kogarah
Query!
Recruitment hospital [2]
0
0
Monash Health - Clayton
Query!
Recruitment hospital [3]
0
0
Cancer Clinical Trials Centre, Austin Health, Level 4 - Heidelberg
Query!
Recruitment hospital [4]
0
0
Genesis Care - Heidelberg
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [3]
0
0
3084 - Heidelberg
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Kentucky
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Louisiana
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Massachusetts
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Michigan
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Minnesota
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
Belgium
Query!
State/province [8]
0
0
Gent
Query!
Country [9]
0
0
Belgium
Query!
State/province [9]
0
0
Leuven
Query!
Country [10]
0
0
Italy
Query!
State/province [10]
0
0
MI
Query!
Country [11]
0
0
Korea, Republic of
Query!
State/province [11]
0
0
Seoul
Query!
Country [12]
0
0
Poland
Query!
State/province [12]
0
0
Lubelskie
Query!
Country [13]
0
0
Poland
Query!
State/province [13]
0
0
Malopolskie
Query!
Country [14]
0
0
Poland
Query!
State/province [14]
0
0
Krakow
Query!
Country [15]
0
0
Poland
Query!
State/province [15]
0
0
Lublin
Query!
Country [16]
0
0
Poland
Query!
State/province [16]
0
0
Zamosc
Query!
Country [17]
0
0
Spain
Query!
State/province [17]
0
0
Caceres
Query!
Country [18]
0
0
Spain
Query!
State/province [18]
0
0
Cáceres
Query!
Country [19]
0
0
Spain
Query!
State/province [19]
0
0
Málaga
Query!
Country [20]
0
0
United Kingdom
Query!
State/province [20]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
EMD Serono
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase
1b followed by Phase 3), parallel-arm study of avelumab in combination with various agents
for the treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02951156
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02951156
Download to PDF